High expression of LY6E is an independent prognostic factor of colorectal cancer patients

Abstract

Colorectal cancer (CRC) is common cancer worldwide, and the 5-year relative survival rate of CRC patients with distant metastasis is as low as 14%. Therefore, identifying markers of CRC is important for the early detection of CRC and applying appropriate treatment strategies. The lymphocyte antigen 6 family (LY6 family) is closely related to the behavior of various cancer types. Among the LY6 family, the lymphocyte antigen 6 complex, locus E (LY6E), which is specifically highly expressed in CRC. Hence, the effects of LY6E on cell function in CRC and its role in CRC recurrence and metastasis were investigated. Reverse transcription-quantitative PCR, western blotting and in vitro functional studies were carried out using four CRC cell lines. Immunohistochemical analysis of 110 CRC tissues was performed to explore the biological functions and expression patterns of LY6E in CRC. LY6E was overexpressed CRC tissues compared with that in adjacent normal tissues. High expression of LY6E in CRC tissues was an independent prognostic factor of worse overall survival (P=0.048). Knockdown of LY6E using small interfering RNA inhibited CRC cell proliferation, migration, invasion, and soft agar colony formation, indicating some of its effects on CRC carcinogenic functions. High expression of LY6E may have oncogenic functions in CRC and be useful as a valuable prognostic marker and potential therapeutic target for CRC.

SNAI2 enhances HPV‑negative cervical cancer cell dormancy by modulating u‑PAR expression and the activity of the ERK/p38 signaling pathway in vitro

“…6 ). The present findings are consistent with the conclusions of Julio et al ( 20 ), which revealed that high ERK1/2 and p38 MAPK activity coexist in promoting the proliferative activity of melanoma M24MET cells ( 32 , 33 ), due to several isoforms of p38MAPK, α, γ and δ ( 24 ). By contrast, SNAI2 could trans-suppress the expression of Akt1/p-Akt1 by binding to E-box motifs in the promoter of the Akt1 gene and then inhibit the cell proliferation and tumor formation, not promote dormancy of cervical cancer cells, by upregulating p21/p27 and/or downregulating the activity of the Wnt/β-catenin signaling pathway ( 24 ).…”

Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells’ Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway

“…The LY6 family genes were found to be located on chromosome 8q24.3, in which human cancer genes are frequently amplified, and researches have pointed out that some LY6 family members play key roles in various tumors [45,46]. LY6A is aberrant expressed in pituitary tumors and can be a tumor-initiating biomarker of lung cancer [47,48]; LY6E can serve as an independent prognostic factor for CC and is closely associated with the migration and invasion of CC [23,24]; and LY6K promotes the progression of bladder, ovarian, and breast cancers [25][26][27][28][29][30].…”

“…High expression of LY6 family members is reportedly associated with poor prognosis of some cancers. High expression of LY6E enhances the progression of CC [23,24]. High expression of LY6K promotes the progression of bladder, ovarian, and breast cancer [25][26][27][28][29][30].…”